Paradigm Capital Management Inc. NY Boosts Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Paradigm Capital Management Inc. NY grew its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 5.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,386,031 shares of the company's stock after buying an additional 69,831 shares during the period. Paradigm Capital Management Inc. NY owned 3.30% of SI-BONE worth $19,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in SIBN. Virtus Fund Advisers LLC purchased a new position in shares of SI-BONE during the fourth quarter worth about $40,000. Mainstream Capital Management LLC acquired a new position in SI-BONE during the fourth quarter worth approximately $53,000. R Squared Ltd acquired a new stake in shares of SI-BONE in the fourth quarter valued at approximately $73,000. KLP Kapitalforvaltning AS purchased a new position in shares of SI-BONE during the fourth quarter worth approximately $97,000. Finally, Proficio Capital Partners LLC acquired a new position in shares of SI-BONE in the 4th quarter valued at $155,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SI-BONE Stock Performance

SIBN traded down $0.04 during trading on Friday, reaching $18.38. The company's stock had a trading volume of 273,310 shares, compared to its average volume of 375,257. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $20.05. The company has a market capitalization of $783.26 million, a price-to-earnings ratio of -19.98 and a beta of 0.82. The company's fifty day moving average price is $15.24 and its 200-day moving average price is $15.19.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. On average, equities analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SIBN. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of SI-BONE in a research note on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial lifted their target price on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th.

Insider Buying and Selling at SI-BONE

In other news, CEO Laura Francis sold 38,504 shares of the company's stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total value of $661,498.72. Following the sale, the chief executive officer now directly owns 302,958 shares in the company, valued at $5,204,818.44. This represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Pisetsky sold 3,459 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $19.66, for a total value of $68,003.94. Following the sale, the senior vice president now directly owns 264,636 shares in the company, valued at approximately $5,202,743.76. The trade was a 1.29% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 92,565 shares of company stock valued at $1,669,871. Insiders own 4.00% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.